BRAIDWELL LP
13F Reported Value
ⓘ$2.7B
Holdings
86
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
BRAIDWELL LP disclosed 86 positions worth $2.7B in its Form 13F-HR for Q2 2026, led by $CAI (Caris Life Sciences, Inc.) at 5.4% of the equity portfolio, followed by $HNGE and $GKOS. During the quarter the fund opened 24 new positions and exited 25 — including a new stake in $HUM and a full exit from $CNTA. The portfolio is most concentrated in Healthcare (85.3% of disclosed assets). All figures are sourced directly from BRAIDWELL LP’s Form 13F-HR filing with the SEC under CIK 1920938.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 69.0#289
Quality
$147.1M8,256,032 sh - 74.9#105
Quality
$110.4M1,330,127 sh - 40.5#2,099
Quality
$82.7M591,927 sh - —
Quality
$81.1M1,996,965 sh - —
Quality
$78.1M879,467 sh - 54.8
Quality
$77.8M654,262 sh - 34.3
Quality
$71.8M4,918,202 sh - —
Quality
$69.6M1,787,318 sh - 24.0
Quality
$68.3M1,131,452 sh ALPHATEC HLDGS INC - NOTE 0.750% 3/1
—Quality
$66.2M69,121,000 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Caris Life Sciences, Inc.$CAI | 69.0#289 | $147.1M | 8,256,032 |
 Hinge Health, Inc.$HNGE | 74.9#105 | $110.4M | 1,330,127 |
 GLAUKOS Corp$GKOS | 40.5#2,099 | $82.7M | 591,927 |
 Edgewise Therapeutics, Inc.$EWTX | — | $81.1M | 1,996,965 |
 Spyre Therapeutics, Inc.$SYRE | — | $78.1M | 879,467 |
 iRhythm Holdings, Inc.$IRTC | 54.8 | $77.8M | 654,262 |
 NEOGENOMICS INC$NEO | 34.3 | $71.8M | 4,918,202 |
 Kodiak Sciences Inc.$KOD | — | $69.6M | 1,787,318 |
 Xenon Pharmaceuticals Inc.$XENE | 24.0 | $68.3M | 1,131,452 |
| ALPHATEC HLDGS INC - NOTE 0.750% 3/1 | — | $66.2M | 69,121,000 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of BRAIDWELL LP's 86 positions.
Showing top 10 of 86 holdings.
Sector Allocation
Healthcare
$2.3B
Technology
$307.2M
Other
$75.7M
Financials
$14.2M
Full Holdings — BRAIDWELL LP (Q2 2026)
All 86 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $CAI | Caris Life Sciences, Inc. | $147.1M | 5.4% | +3% | 69 |
| 2 | $HNGE | Hinge Health, Inc. | $110.4M | 4.1% | -9% | 74.9 |
| 3 | $GKOS | GLAUKOS Corp | $82.7M | 3.1% | -22% | 40.5 |
| 4 | $EWTX | Edgewise Therapeutics, Inc. | $81.1M | 3.0% | -15% | — |
| 5 | $SYRE | Spyre Therapeutics, Inc. | $78.1M | 2.9% | -6% | — |
| 6 | $IRTC | iRhythm Holdings, Inc. | $77.8M | 2.9% | +7% | 54.8 |
| 7 | $NEO | NEOGENOMICS INC | $71.8M | 2.6% | -12% | 34.3 |
| 8 | $KOD | Kodiak Sciences Inc. | $69.6M | 2.6% | -2% | — |
| 9 | $XENE | Xenon Pharmaceuticals Inc. | $68.3M | 2.5% | -15% | 24 |
| 10 | — | ALPHATEC HLDGS INC - NOTE 0.750% 3/1 | $66.2M | 2.5% | +12% | — |
| 11 |  $GLUE | Monte Rosa Therapeutics, Inc. | $59.3M | 2.2% | -24% | 30.3 |
| 12 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $58.0M | 2.1% | -34% | 22.6 |
| 13 |  $NBIX | NEUROCRINE BIOSCIENCES INC | $56.7M | 2.1% | -48% | 76.5 |
| 14 |  $ATEC | Alphatec Holdings, Inc. | $56.5M | 2.1% | +201% | 43.3 |
| 15 |  $GENB | Generate Biomedicines, Inc. | $55.4M | 2.0% | -9% | — |
| 16 |  $MRVI | MARAVAI LIFESCIENCES HOLDINGS, INC. | $54.3M | 2.0% | -15% | 24.4 |
| 17 |  $KRYS | Krystal Biotech, Inc. | $47.9M | 1.8% | -29% | 79.2 |
| 18 |  $HUM | HUMANA INC | $45.5M | 1.7% | NEW | 58.9 |
| 19 |  $TMO | THERMO FISHER SCIENTIFIC INC. | $44.8M | 1.7% | -4% | 65.1 |
| 20 |  $KYMR | Kymera Therapeutics, Inc. | $43.4M | 1.6% | +12% | 28.4 |
| 21 |  $RYTM | RHYTHM PHARMACEUTICALS, INC. | $42.3M | 1.6% | +23% | 33.9 |
| 22 |  $DMRA | Damora Therapeutics, Inc. | $42.1M | 1.6% | +81% | — |
| 23 |  $ACAD | ACADIA PHARMACEUTICALS INC | $41.7M | 1.5% | -33% | 67.8 |
| 24 |  $BTSG | BrightSpring Health Services, Inc. | $41.6M | 1.5% | -41% | 63.3 |
| 25 |  $TMDX | TransMedics Group, Inc. | $40.5M | 1.5% | +85% | 67.2 |
| 26 |  $MBX | MBX Biosciences, Inc. | $39.2M | 1.4% | -52% | — |
| 27 |  $CLYM | Climb Bio, Inc. | $36.5M | 1.4% | +83% | — |
| 28 |  $CDNA | CareDx, Inc. | $34.8M | 1.3% | -44% | 67.5 |
| 29 |  $MAZE | Maze Therapeutics, Inc. | $34.0M | 1.3% | NEW | 10.3 |
| 30 |  $DRUG | BRIGHT MINDS BIOSCIENCES INC. | $34.0M | 1.3% | -10% | — |
| 31 |  $ACHC | Acadia Healthcare Company, Inc. | $33.7M | 1.3% | +77% | 36.7 |
| 32 |  $NKTR | NEKTAR THERAPEUTICS | $33.1M | 1.2% | +113% | 9.7 |
| 33 |  $CRVS | Corvus Pharmaceuticals, Inc. | $31.8M | 1.2% | +21% | — |
| 34 |  $NRIX | Nurix Therapeutics, Inc. | $31.2M | 1.1% | -27% | 6.4 |
| 35 |  $INSP | Inspire Medical Systems, Inc. | $30.2M | 1.1% | +0% | 63.7 |
| 36 |  $AVTX | Avalo Therapeutics, Inc. | $30.1M | 1.1% | NEW | 11.7 |
| 37 |  $ALMR | Alamar Biosciences, Inc. | $29.4M | 1.1% | NEW | — |
| 38 |  $DHR | DANAHER CORP /DE/ | $28.7M | 1.1% | +8% | 64.8 |
| 39 |  $ISRG | INTUITIVE SURGICAL INC | $27.9M | 1.0% | -9% | 79.9 |
| 40 |  $ORKA | Oruka Therapeutics, Inc. | $26.5M | 1.0% | NEW | — |
| 41 |  $AVLN | Avalyn Pharma Inc. | $26.4M | 1.0% | NEW | — |
| 42 |  $AVAH | Aveanna Healthcare Holdings, Inc. | $26.3M | 1.0% | +39% | 65.6 |
| 43 |  $BIOA | BioAge Labs, Inc. | $25.3M | 0.9% | -14% | 26.8 |
| 44 |  $BSX | BOSTON SCIENTIFIC CORP | $25.1M | 0.9% | +70% | 77.5 |
| 45 |  $VERA | Vera Therapeutics, Inc. | $24.2M | 0.9% | +8% | — |
| 46 |  $RGEN | REPLIGEN CORP | $24.2M | 0.9% | +273% | 58.4 |
| 47 |  $ZURA | Zura Bio Ltd | $23.5M | 0.9% | -0% | — |
| 48 |  $GH | Guardant Health, Inc. | $22.2M | 0.8% | -70% | 39 |
| 49 |  $EOLS | Evolus, Inc. | $21.9M | 0.8% | +2% | 39 |
| 50 |  $NTRA | Natera, Inc. | $21.6M | 0.8% | -38% | 53.5 |
| 51 |  $KIDS | ORTHOPEDIATRICS CORP | $21.1M | 0.8% | +0% | 37.8 |
| 52 |  $ELV | Elevance Health, Inc. | $20.9M | 0.8% | -13% | 59 |
| 53 |  $TECX | Tectonic Therapeutic, Inc. | $20.5M | 0.8% | -30% | — |
| 54 |  $DYN | Dyne Therapeutics, Inc. | $20.5M | 0.8% | -45% | — |
| 55 | $NEO | NEOGENOMICS INC | $16.9M | 0.6% | -82% | 34.3 |
| 56 |  $IMCR | Immunocore Holdings plc | $16.6M | 0.6% | NEW | — |
| 57 | $RGEN | REPLIGEN CORP | $16.4M | 0.6% | -84% | 58.4 |
| 58 |  $ARGX | ARGENX SE | $16.4M | 0.6% | -79% | — |
| 59 |  $CLDX | Celldex Therapeutics, Inc. | $16.2M | 0.6% | -68% | 8.4 |
| 60 |  $OVID | Ovid Therapeutics Inc. | $15.9M | 0.6% | NEW | 26.4 |
| 61 |  $MNKD | MANNKIND CORP | $14.7M | 0.5% | NEW | 37.2 |
| 62 |  $QURE | uniQure N.V. | $13.9M | 0.5% | NEW | — |
| 63 |  $XFOR | X4 Pharmaceuticals, Inc | $13.6M | 0.5% | -11% | 28 |
| 64 |  $ORIC | Oric Pharmaceuticals, Inc. | $13.2M | 0.5% | +8% | — |
| 65 |  $KNSA | Kiniksa Pharmaceuticals International, plc | $11.8M | 0.4% | -33% | — |
| 66 |  $OCS | Oculis Holding AG | $11.6M | 0.4% | NEW | — |
| 67 |  $ACRS | Aclaris Therapeutics, Inc. | $11.3M | 0.4% | +26% | 12 |
| 68 |  $SPTX | Seaport Therapeutics, Inc. | $10.9M | 0.4% | NEW | — |
| 69 |  $VOR | Vor Biopharma Inc. | $10.6M | 0.4% | +23% | — |
| 70 |  $SRZN | Surrozen, Inc./DE | $10.1M | 0.4% | -1% | — |
| 71 |  $IMUX | IMMUNIC, INC. | $9.9M | 0.4% | NEW | — |
| 72 | — | HELIX ACQUISITION CORP III - USD CL A ORD SHS | $9.5M | 0.3% | +0% | — |
| 73 |  $IONS | IONIS PHARMACEUTICALS INC | $9.3M | 0.3% | -11% | 23.4 |
| 74 |  $DGX | QUEST DIAGNOSTICS INC | $9.2M | 0.3% | NEW | 69 |
| 75 |  $ANL | Adlai Nortye Group Ltd. | $9.1M | 0.3% | NEW | — |
| 76 |  $TENX | TENAX THERAPEUTICS, INC. | $8.5M | 0.3% | NEW | — |
| 77 |  $KARD | Kardigan, Inc. | $7.2M | 0.3% | NEW | — |
| 78 |  $AMAN | Amanat Acquisition Corp. | $7.1M | 0.3% | NEW | — |
| 79 |  $COAG | Hemab Therapeutics Holdings, Inc. | $5.9M | 0.2% | NEW | — |
| 80 |  $GHRS | GH Research PLC | $5.6M | 0.2% | NEW | — |
| 81 |  $WAT | WATERS CORP /DE/ | $5.3M | 0.2% | NEW | 60.4 |
| 82 |  $RACC | Research Alliance Corp III | $4.3M | 0.2% | NEW | — |
| 83 |  $JATT | JATT II Acquisition Corp. | $2.8M | 0.1% | NEW | — |
| 84 |  $LUNG | Pulmonx Corp | $978,303 | 0.0% | +0% | 23.4 |
| 85 |  $YARW | Yarrow Bioscience, Inc. | $596,091 | 0.0% | +0% | — |
| 86 |  $CYCN | Cyclerion Therapeutics, Inc. | $531,857 | 0.0% | NEW | — |
New Positions (24)
$HUM HUMANA INC$45.5M$MAZE Maze Therapeutics, Inc.$34.0M$AVTX Avalo Therapeutics, Inc.$30.1M$ALMR Alamar Biosciences, Inc.$29.4M$ORKA Oruka Therapeutics, Inc.$26.5M$AVLN Avalyn Pharma Inc.$26.4M$IMCR Immunocore Holdings plc$16.6M$OVID Ovid Therapeutics Inc.$15.9M$MNKD MANNKIND CORP$14.7M$QURE uniQure N.V.$13.9M$OCS Oculis Holding AG$11.6M$SPTX Seaport Therapeutics, Inc.$10.9M$IMUX IMMUNIC, INC.$9.9M$DGX QUEST DIAGNOSTICS INC$9.2M$ANL Adlai Nortye Group Ltd.$9.1MExited Positions (25)
$CNTA Centessa Pharmaceuticals plc
$NUVL Nuvalent, Inc.
$CGON CG Oncology, Inc.
$APGE Apogee Therapeutics, Inc.
$PEN Penumbra Inc
$SLNO SOLENO THERAPEUTICS INC
$ILMN ILLUMINA, INC.
$BMRN BIOMARIN PHARMACEUTICAL INC
$ESTA ESTABLISHMENT LABS HOLDINGS INC.
$FULC Fulcrum Therapeutics, Inc.
$CVS CVS HEALTH Corp
$TARS Tarsus Pharmaceuticals, Inc.
$ENGN enGene Therapeutics Inc.
$TGTX TG THERAPEUTICS, INC.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for BRAIDWELL LP including:
Track BRAIDWELL LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for BRAIDWELL LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: BRAIDWELL LP
13F Pro is an AI hedge fund tracker and stock research platform. For BRAIDWELL LP (SEC CIK: 1920938), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in BRAIDWELL LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.